Form 4: U.S. Physical Therapy CEO Christopher Reading Sells Shares
SEC Form 4
Christopher Reading, Chairman and CEO of U.S. Physical Therapy, Inc., reports the sale of company stock in two transactions.
Summary
- Christopher Reading, the Chairman and CEO of U.S. Physical Therapy Inc., sold 1,100 shares of common stock on May 28, 2024, at a weighted average price of $102.13 per share.
- He then sold 1,000 shares on May 29, 2024, at a weighted average price of $100.13 per share.
- Following these transactions, Reading directly owns 98,738 shares of U.S. Physical Therapy, Inc.
- This total includes 32,913 shares of restricted stock that will vest in tranches between July 1, 2024, and January 1, 2028, contingent on his continued employment as an officer of the company.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports factual transactions. Insider selling can sometimes be interpreted negatively, but without additional context, it's difficult to assess the impact.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Comparing Christopher Reading's transactions to those of other CEOs in the healthcare services industry, such as Tenet Healthcare's Saum Sutaria or HCA Healthcare's Samuel Hazen, would provide context.
- Analyzing the frequency and size of insider sales relative to their total holdings and company performance can reveal trends.
- For example, if Sutaria or Hazen were selling similar proportions of their holdings, it might indicate a broader industry trend or personal financial planning rather than a specific concern about their respective companies.
Stakeholder Impact
- Shareholders may interpret insider selling as a lack of confidence in the company's future prospects, potentially leading to a decrease in stock price.
- However, it could also be viewed as a normal part of personal financial planning for the executive.
Key Dates
| Date | Description |
|---|---|
| 05/28/2024 | Christopher Reading sold 1,100 shares of common stock. |
| 05/29/2024 | Christopher Reading sold 1,000 shares of common stock and filed the Form 4. |
| 07/01/2024 | 3,587 restricted shares lapse. |
| 10/01/2024 | 3,587 restricted shares lapse. |
| 01/01/2025 | 3,588 restricted shares lapse. |
| 04/01/2025 | 2,887 restricted shares lapse. |
| 07/01/2025 | 2,887 restricted shares lapse. |
| 10/01/2025 | 2,887 restricted shares lapse. |
| 01/01/2026 | 2,888 restricted shares lapse. |
| 04/01/2026 | 1,637 restricted shares lapse. |
| 07/01/2026 | 1,637 restricted shares lapse. |
| 10/01/2026 | 1,637 restricted shares lapse. |
| 01/01/2027 | 1,638 restricted shares lapse. |
| 04/01/2027 | 1,012 restricted shares lapse. |
| 07/01/2027 | 1,012 restricted shares lapse. |
| 10/01/2027 | 1,012 restricted shares lapse. |
| 01/01/2028 | 1,017 restricted shares lapse. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.